{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:53:41Z","timestamp":1788429221489,"version":"build-2803163510"},"reference-count":12,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jid.2018.02.020","type":"journal-article","created":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T09:31:22Z","timestamp":1526895082000},"page":"1249-1251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Modes of Action of Intravenous Immunoglobulin in Bullous Pemphigoid"],"prefix":"10.1016","volume":"138","author":[{"given":"Ning","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Culton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2018.02.020_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A\u00a0randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2018.02.020_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-3083.1999.tb00801.x","article-title":"Increased serum IL-6, TNF-alpha and IL-10 levels in patients with bullous pemphigoid: relationships with disease activity","volume":"12","author":"D'Auria","year":"1999","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2018.02.020_bib3","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2018.02.020_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jid.2018.02.020_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0923-1811(97)00044-3","article-title":"Increased serum levels of interleukin (IL)-5, IL-6 and IL-8 in bullous pemphigoid","volume":"16","author":"Inaoki","year":"1998","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2018.02.020_bib6","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3389\/fimmu.2017.01669","article-title":"Anti-idiotypic antibodies against BP-IgG prevent type XVII collagen depletion","volume":"8","author":"Kamaguchi","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2018.02.020_bib7","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2018.02.020_bib8","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1172\/JCI116856","article-title":"A\u00a0passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180","volume":"92","author":"Liu","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2018.02.020_bib9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0092-8674(00)00087-8","article-title":"The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B\/MMP-9\u00a0in\u00a0vivo","volume":"102","author":"Liu","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.jid.2018.02.020_bib10","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jid.2018.01.005","article-title":"Intravenous IgG reduces pathogenic autoantibodies, serum IL-6 levels and disease severity in experimental bullous pemphigoid models","volume":"138","author":"Sasaoka","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2018.02.020_bib11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2018.02.020_bib12","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.4049\/jimmunol.0903101","article-title":"A\u00a0novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen","volume":"184","author":"Ujiie","year":"2010","journal-title":"J\u00a0Immunol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18301453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18301453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T12:53:50Z","timestamp":1561121630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X18301453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0022202X18301453"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2018.02.020","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modes of Action of Intravenous Immunoglobulin in Bullous Pemphigoid","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2018.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2018.01.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}